Efficacy of Biodegradable Curcumin Nanoparticles in Delaying Cataract in Diabetic Rat Model

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Grama, Charitra N ^a   Suryanarayana, Palla ^b   Patil, Madhoosudan A ^b   Raghu, Ganugula ^b   Balakrishna, Nagalla ^b   Ravi Kumar, M N V ^a   Reddy, Geereddy Bhanuprakash ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NATIONAL INSTITUTE OF NUTRITION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTALLIN; CURCUMIN; NANOCURCUMIN; NANOPARTICLE; POLYGLACTIN; POLYOL; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BIODEGRADABILITY; CATARACT; CONTROLLED STUDY; DISEASE COURSE; ENCAPSULATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; RAT; RAT MODEL; SOLUBILIZATION; STREPTOZOCIN DIABETES;

ALDEHYDE REDUCTASE; ANIMALS; ANTIOXIDANTS; BIOCOMPATIBLE MATERIALS; BIODEGRADATION, ENVIRONMENTAL; BLOOD GLUCOSE; BODY WEIGHT; CATARACT; CRYSTALLINS; CURCUMIN; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEEDING BEHAVIOR; INSULIN; LACTIC ACID; LENS, CRYSTALLINE; MALONDIALDEHYDE; NANOPARTICLES; OXIDATIVE STRESS; POLYGLYCOLIC ACID; PROTEIN CARBONYLATION; RATS; SORBITOL; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 84885396132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078217     Document Type: Article

References (34)

1. (2011) Internal Diabetes Federation, Diabetes Atlas 5th edition.
2. Michael J, Fowler MD, (2008) Microvascular and Macrovascular Complications of Diabetes. Clin Diabetes 26: 77-82. doi:10.2337/diaclin.26.2.77.
3. Congdon NG, Lietman T, (2003) Important Causes of Visual Impairment in the World Today JAMA 290: 2057-2060. doi:10.1001/jama.290.15.2057. PubMed: 14559961.
4. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820. doi:10.1038/414813a. PubMed: 11742414.
5. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, et al. (2000) Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 23: 1113-1118. doi:10.2337/diacare.23.8.1113. PubMed: 10937507.
6. Spector A, (2000) Review: Oxidative stress and disease. J Ocul Pharmacol Ther 16: 193-201. doi:10.1089/jop.2000.16.193. PubMed: 10803430.
7. Kyselova Z, Stefek M, Bauer V, (2004) Pharmacological prevention of diabetic cataract. J Diabetes Complications 18: 129-140. doi:10.1016/S1056-8727(03)00009-6. PubMed: 15120709.
8. Mares JA, (2004) High-dose antioxidant supplementation and cataract risk. Nutr Rev 62: 28-32. doi:10.1301/nr.2004.jan.28-32. PubMed: 14995054.
9. Taylor A, Jacques PF, Epstein EM, (1995) Relations among aging, antioxidant status, and cataract. Am J Clin Nutr 62: 1439S-1447S. PubMed: 7495245.
10. Kumar PA, Reddy PY, Srinivas PN, Reddy GB, (2009) Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of alpha-crystallin chaperone activity. J Nutr Biochem 20: 553-562. doi:10.1016/j.jnutbio.2008.05.015. PubMed: 18789666.
11. Saraswat M, Suryanarayana P, Reddy PY, Patil MA, Balakrishna N, et al. (2010) Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Mol Vis 16: 1525-1537. PubMed: 20806076.
12. Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K, et al. (2005) Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 46: 2092-2099. doi:10.1167/iovs.04-1304. PubMed: 15914628.
13. Suryanarayana P, Saraswat M, Petrash JM, Reddy GB, (2007) Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Mol Vis 13: 1291-1297. PubMed: 17679931.
14. Mrudula T, Suryanarayana P, Srinivas PN, Reddy GB, (2007) Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem Biophys Res Commun 361: 528-532. doi:10.1016/j.bbrc.2007.07.059. PubMed: 17662242.
15. Muthenna P, Suryanarayana P, Gunda SK, Petrash JM, Reddy GB, (2009) Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Lett 583: 3637-3642. doi:10.1016/j.febslet.2009.10.042. PubMed: 19850041.
16. Krishnaswamy K, Raghuramulu N, (1998) Bioactive phytochemicals with emphasis on dietary practices. Indian J Med Res 108: 167-181. PubMed: 9863273.
17. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB, (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818. doi:10.1021/mp700113r. PubMed: 17999464.
18. Sharma RA, Steward WP, Gescher AJ, (2007) Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 595: 453-470. doi:10.1007/978-0-387-46401-5_20. PubMed: 17569224.
19. Pan MH, Huang TM, Lin JK, (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27: 486-494. PubMed: 10101144.
20. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854. doi:10.1158/1078-0432.CCR-04-0744. PubMed: 15501961.
21. Kumar Ravi (2012) Can efficient delivery systems leverage benefits of antioxidants leading to potential medicines? Drug Discov Today 17: 407-408. doi:10.1016/j.drudis.2012.01.024. PubMed: 22326671.
22. Grama CN, Ankola DD, Ravi Kumar MNV, (2011) Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives. Curr Opin_Colloid Interface Sci 16: 238-245. doi:10.1016/j.cocis.2010.11.005.
23. Italia JL, Sharp A, Carter KC, Warn P, Kumar MN, (2011) Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome(R) or Fungizone. PLOS ONE 6: e25744. doi:10.1371/journal.pone.0025744. PubMed: 21998690.
24. Mittal G, Carswell H, Brett R, Currie S, Kumar MN, (2011) Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. J Control Release 150: 220-228. doi:10.1016/j.jconrel.2010.11.013. PubMed: 21111014.
25. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN, (2009) Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37: 223-230. doi:10.1016/j.ejps.2009.02.019. PubMed: 19491009.
26. Reddy PY, Giridharan NV, Reddy GB, (2012) Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. Mol Vis 18: 495-503. PubMed: 22393276.
27. Aggarwal BB, Kumar A, Bharti AC, (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398. PubMed: 12680238.
28. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, et al. (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76: 1590-1611. doi:10.1016/j.bcp.2008.08.008. PubMed: 18775680.
29. Premanand C, Rema M, Sameer MZ, Sujatha M, Balasubramanyam M, (2006) Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest Ophthalmol Vis Sci 47: 2179-2184. doi:10.1167/iovs.05-0580. PubMed: 16639030.
30. Kowluru RA, Kanwar M, (2007) Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond) 4: 8. doi:10.1186/1743-7075-4-8. PubMed: 17437639.
31. Vasireddy V, Chavali VR, Joseph VT, Kadam R, Lin JH, et al. (2011) Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLOS ONE 6: e21193. doi:10.1371/journal.pone.0021193. PubMed: 21738619.
32. Suryanarayana P, Krishnaswamy K, Reddy GB, (2003) Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis 9: 223-230. PubMed: 12802258.
33. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K, (2009) Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem 57: 9141-9146. doi:10.1021/jf9013923. PubMed: 19757811.
34. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, et al. (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79: 330-338. doi:10.1016/j.bcp.2009.09.003. PubMed: 19735646.